Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor-


Journal

Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550

Informations de publication

Date de publication:
01 2021
Historique:
received: 19 05 2020
accepted: 02 10 2020
pubmed: 23 10 2020
medline: 18 1 2022
entrez: 22 10 2020
Statut: ppublish

Résumé

Hypoxia-inducible factor (HIF) is associated with the expression of CYP, but the underlying mechanism remains uncertain. In this study, we investigated the effect of HIF-

Identifiants

pubmed: 33087449
pii: dmd.120.000124
doi: 10.1124/dmd.120.000124
doi:

Substances chimiques

Constitutive Androstane Receptor 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
NR1I2 protein, human 0
Pregnane X Receptor 0
Prolyl-Hydroxylase Inhibitors 0
Retinoid X Receptors 0
EGLN1 protein, human EC 1.14.11.2
Hypoxia-Inducible Factor-Proline Dioxygenases EC 1.14.11.29
CYP1A2 protein, human EC 1.14.14.1
CYP2B6 protein, human EC 1.14.14.1
Cytochrome P-450 CYP1A2 EC 1.14.14.1
Cytochrome P-450 CYP2B6 EC 1.14.14.1
Cytochrome P-450 CYP3A EC 1.14.14.1
CYP3A4 protein, human EC 1.14.14.55

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-30

Informations de copyright

Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Hiroki Takano (H)

Drug Safety and Pharmacokinetics Laboratories (H.T., J.Y., M.T., H.E.), Pharmacology Laboratories (S.K.), and Chemistry Laboratories (M.H.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan hir-takano@taisho.co.jp.

Jun-Ichi Yamaguchi (JI)

Drug Safety and Pharmacokinetics Laboratories (H.T., J.Y., M.T., H.E.), Pharmacology Laboratories (S.K.), and Chemistry Laboratories (M.H.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

Sota Kato (S)

Drug Safety and Pharmacokinetics Laboratories (H.T., J.Y., M.T., H.E.), Pharmacology Laboratories (S.K.), and Chemistry Laboratories (M.H.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

Makoto Hamada (M)

Drug Safety and Pharmacokinetics Laboratories (H.T., J.Y., M.T., H.E.), Pharmacology Laboratories (S.K.), and Chemistry Laboratories (M.H.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

Mika Tada (M)

Drug Safety and Pharmacokinetics Laboratories (H.T., J.Y., M.T., H.E.), Pharmacology Laboratories (S.K.), and Chemistry Laboratories (M.H.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

Hiromi Endo (H)

Drug Safety and Pharmacokinetics Laboratories (H.T., J.Y., M.T., H.E.), Pharmacology Laboratories (S.K.), and Chemistry Laboratories (M.H.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH